- 著者
-
藤井 節郎
中村 芳正
武田 節夫
森田 健一
佐藤 俊幸
丸中 照義
川口 安郎
采見 憲男
- 出版者
- The Japanese Cancer Association
- 雑誌
- GANN Japanese Journal of Cancer Research (ISSN:0016450X)
- 巻号頁・発行日
- vol.71, no.1, pp.30-44, 1980-02-29 (Released:2008-10-23)
- 参考文献数
- 14
The metabolism, antitumor activity, and acute toxicity of 5-fluoro-1, 3-bis-(tetrahydro-2-furanyl)-2, 4-pyrimidinedione (FD-1) were investigated in animals, compared with 5-fluoro-1-(tetrahydro-2-furanyl)-2, 4-pyrimidinedione (FT). It was found that after oral administration of FD-1, the level of 5-fluorouracil (5-FU) was maintained higher and longer than after administration of FT, and that a large amount of 5-FU was released from FD-1 by liver microsomal drugmetabolizing enzymes or spontaneous hydrolysis via 5-fluoro-3-(tetrahydro-2-furanyl)-2, 4-pyrimidinedione (3-FT) and FT. FD-1 had a significant activity against the solid form of Ehrlich carcinoma, sarcoma-180, hepatoma AH130, Yoshida sarcoma, Walker carcinosarcoma-256, and leukemia L1210 and P388, but not the ascitic forms, and it produced greater inhibition of tumor growth than FT. The acute toxicity of FD-1 was less than that of FT.